文献速递皮肤肿瘤

黑素瘤生存者子女的黑素瘤预防:一项随机临床试验

Melanoma Prevention Among Children of Melanoma Survivors: A Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2026-10-07

这项随机临床试验将364对黑素瘤生存者-子女配对分配至FLARE行为干预或主动教育对照,两组均通过远程医疗实施4周。FLARE未能在随时间推移中减少儿童晒伤,但改善了儿童的防晒行为,并在首次干预后评估时与较低的儿童报告晒伤相关。

要点

  • FLARE干预未显著减少儿童晒伤随时间的发生。
  • FLARE组儿童防晒行为从基线至第二次干预后评估的改善优于对照组。
  • 首次干预后评估时FLARE组儿童报告晒伤低于对照组。

核心结论

  • FLARE干预与主动教育对照相比未能减少儿童随时间的晒伤。
  • FLARE改善了儿童防晒行为,并与干预后即刻较低的儿童报告晒伤相关。
  • 可能需要额外策略以实现高风险儿童晒伤的持续减少。

研究设计与样本

  • 通过癌症登记处及全州和临床数据库招募黑素瘤生存者-子女配对。
  • 纳入标准为确诊黑素瘤的生存者及至少1名8至17岁、前一年有1次或以上晒伤的子女。
  • 520名合格生存者中,364对配对入组、完成基线评估并随机化。
  • 两种条件均为4周远程医疗教育模块,FLARE含家族黑素瘤风险教育和针对儿童防晒的技能构建,对照含识别可靠健康信息来源的一般皮肤癌教育。

主要发现

  • 主要分析纳入364对配对(FLARE 180对[49.5%],对照184对[50.5%])进行意向性治疗分析,未发现组间晒伤变化率随时间的显著差异。
  • 首次干预后评估时,FLARE组儿童报告晒伤低于对照组(B = -0.17;95% CI,-0.30至-0.04;P = .01)。
  • 与对照组相比,FLARE组儿童防晒行为从基线至第二次干预后评估的改善更大(B = 0.26;95% CI,0.14-0.38;P < .001)。
  • 意图性或非意图性晒黑行为两组无显著差异,基线报告较少。

临床怎么用

  • FLARE可改善黑素瘤生存者子女的防晒行为。
  • FLARE在干预后即刻可能降低儿童报告晒伤,但长期减少晒伤需额外策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Children of melanoma survivors have a 2-fold increased lifetime risk of melanoma, yet they inconsistently practice sun protection and experience preventable sunburns. OBJECTIVE: To evaluate a telehealth-delivered behavioral intervention for skin cancer prevention among children of melanoma survivors. DESIGN, SETTING, AND PARTICIPANTS: This parallel-group randomized clinical trial assigned survivor-child dyads to the family, lifestyles, actions, and risk education (FLARE) intervention or a control condition between April 2020 and October 2023. Participants were recruited through a cancer registry and statewide and clinical databases. Eligible survivors had a confirmed melanoma diagnosis and at least 1 child aged 8 to 17 years with 1 or more sunburns during the previous year. Of 520 eligible survivors, 364 dyads enrolled, completed baseline assessment, and were randomized. Data were analyzed from 2025 to 2026. INTERVENTIONS: Both conditions were telehealth education modules delivered over 4 weeks. FLARE included familial melanoma risk education and skills building that targeted child sun protection. The control included general skin cancer education on identifying reputable sources of health information. MAIN OUTCOMES AND MEASURES: The primary outcome was child sunburn occurrence, which was evaluated as the change from baseline through the 2 postintervention assessments. Secondary outcomes included child sun-protective behaviors and tanning. RESULTS: A total of 364 survivor-child dyads were recruited and randomized (parents: mean [SD] age, 45.1 [6.2] years; 228 female individuals [62.6%]; children: mean [SD] age, 12.9 [2.6] years; 189 female individuals [51.9%]). The primary analysis, which included 364 dyads (180 FLARE [49.5%], 184 control [50.5%]) in the intention-to-treat analyses, found no significant between-group differences in rate of sunburn change across time. However, at the first postintervention assessment, child-reported sunburn occurrence was lower in the FLARE group compared with the control group (B = -0.17; 95% CI, -0.30 to -0.04; P = .01). Relative to the control group, FLARE participants demonstrated greater increases in child sun-protective behaviors from baseline through the second postintervention assessment (B = 0.26; 95% CI, 0.14-0.38; P < .001). No significant between-group differences were observed for intentional or unintentional tanning, which were infrequently reported at baseline. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, FLARE failed to reduce child sunburn over time compared with an active educational control. Although FLARE improved sun-protective behaviors and was associated with lower child-reported sunburn immediately postintervention, additional strategies may be needed for sustained reductions in high-risk children. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04201223.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Wu YP, Stump TK, Deboeck PR, et al. Melanoma Prevention Among Children of Melanoma Survivors: A Randomized Clinical Trial. JAMA Dermatol. 2026. PMID: 42842243. doi:10.1001/jamadermatol.2026.3877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。